23 research outputs found
FISH analysis of hematological neoplasias with 1p36 rearrangements allows the definition of a cluster of 2.5 Mb included in the minimal region deleted in 1p36 deletion syndrome
Rearrangements in the distal region of the short arm of chromosome 1 are recurrent aberrations in a broad spectrum of human neoplasias. However, neither the location of the breakpoints (BP) on 1p36 nor the candidate genes have been fully determined. We have characterized, by fluorescence in situ hybridization (FISH), the BP in 26 patients with hematological neoplasias and 1p36 rearrangements in the G-banding karyotype. FISH allowed a better characterization of all samples analyzed. Nine cases (35%) showed reciprocal translocations, 15 (58%) unbalanced rearrangements, and two (7%) deletions. We describe two new recurrent aberrations. In 18 of the 26 cases analyzed the BP were located in band 1p36, which is 25.5 Mb long. In 14 of these 18 cases (78%) and without distinction between myeloid and lymphoid neoplasias, the BP clustered in a 2.5 Mb region located between 1p36.32 and the telomere. Interestingly, this region is contained in the 10.5 Mb cluster on 1p36.22-1pter defined in cases with 1p36 deletion syndrome. The 2.5 Mb region, located on 1p36.32-1pter, has a higher frequency of occurrence of tandem repeats and segmental duplications larger than 1 kb, when compared with the 25.5 Mb of the complete 1p36 band. This could explain its proneness for involvement in chromosomal rearrangements in hematological neoplasias
Comparative genomic hybridization and amplotyping by arbitrarily primed PCR in stage A B-CLL
Cytogenetic analysis is useful in the diagnosis and to assess prognosis of B-cell chronic lymphocytic leukemia (B-CLL). However, successful cytogenetics by standard techniques has been hindered by the low in vitro mitotic activity of the malignant B-cell population. Fluorescence in situ hybridization (FISH) has become a useful tool, but it does not provide an overall view of the aberrations. To overcome this hurdle, two DNA-based techniques have been tested in the present study: comparative genomic hybridization (CGH) and amplotyping by arbitrarily primed PCR (AP-PCR). Comparative genomic hybridization resolution depends upon the 400-bands of the human standard karyotype. AP-PCR allows detection of allelic losses and gains in tumor cells by PCR fingerprinting, thus its resolution is at the molecular level. Both techniques were performed in 23 patients with stage A B-CLL at diagnosis. The results were compared with FISH. The sensitivity of AP-PCR was greater than CGH (62% vs. 43%). The use of CGH combined with AP-PCR allowed to detect genetic abnormalities in 79% (15/19) of patients in whom G-banding was not informative, providing a global view of the aberrations in a sole experiment. This study shows that combining these two methods with FISH, makes possible a more precise genetic characterization of patients with B-CLL
NUP98 is fused to HOXA9 in a variant complex t(7;11;13;17) in a patient with AML-M2
The t(7;11)(p15;p15.4) has been reported to fuse the NUP98 gene (11p15), a component of the nuclear pore complex, with the class-1 homeobox gene HOXA9 at 7p15. This translocation has been associated with myeloid leukemias, predominantly acute myeloid leukemia (AML) M2 subtype with trilineage myelodysplastic features, and with a poor prognosis. The derived fusion protein retains the FG repeat motif of NUP98 N-terminus and the homeodomain shared by the HOX genes, acting as an oncogenic transcription factor critical for leukemogenesis. We report here a new complex t(7;11)-variant, i.e., t(7;11;13;17)(p15;p15;p?;p1?2) in a patient with AML-M2 and poor prognosis. The NUP98-HOXA9 fusion transcript was detected by RT-PCR, suggesting its role in the malignant transformation as it has been postulated for other t(7;11)-associated leukemias. No other fusion transcripts involving the NUP98 or HOXA9 genes were present, although other mechanisms involving several genes on chromosomes 13 and 17 may also be involved. To our knowledge, this is the first t(7;11) variant involving NUP98 described in hematological malignancies
Consensus guidelines for the use and interpretation of angiogenesis assays
The formation of new blood vessels, or angiogenesis, is a complex process that plays important roles in growth and development, tissue and organ regeneration, as well as numerous pathological conditions. Angiogenesis undergoes multiple discrete steps that can be individually evaluated and quantified by a large number of bioassays. These independent assessments hold advantages but also have limitations. This article describes in vivo, ex vivo, and in vitro bioassays that are available for the evaluation of angiogenesis and highlights critical aspects that are relevant for their execution and proper interpretation. As such, this collaborative work is the first edition of consensus guidelines on angiogenesis bioassays to serve for current and future reference
Evaluation of multiple serum markers in advanced melanoma
The aim of this retrospective study was to
analyse in advanced melanoma the potential tumor markers
S-100B, melanoma inhibiting activity protein (MIA) and
YKL-40 compared to LDH. Serum levels of S-100B, MIA,
LDH and YKL-40 were measured in 110 patients with
advanced melanoma (36 in stage IIIB/C and 74 in stage
IV), in 66 disease-free patients and in 65 healthy controls.
Results show that S-100B, MIA and LDH levels were
significantly higher in patients with advanced melanoma
than in disease-free patients or healthy controls. The
combination of S-100B plus MIA had the best diagnostic
sensitivity, and the addition of LDH did not further increase
this sensitivity. MIA was an independent prognostic factor
of overall survival. Patients with both S-100B and MIA
elevated had a significant shorter survival than those with
both S-100B and MIA under the cut-off. YKL-40 levels did
not differentiate patients with advanced melanoma from
controls. We concluded that the combination of MIA plus
S-100B showed a better prognostic value in advanced
melanoma compared to LDH
FISH analysis of hematological neoplasias with 1p36 rearrangements allows the definition of a cluster of 2.5 Mb included in the minimal region deleted in 1p36 deletion syndrome
Rearrangements in the distal region of the short arm of chromosome 1 are recurrent aberrations in a broad spectrum of human neoplasias. However, neither the location of the breakpoints (BP) on 1p36 nor the candidate genes have been fully determined. We have characterized, by fluorescence in situ hybridization (FISH), the BP in 26 patients with hematological neoplasias and 1p36 rearrangements in the G-banding karyotype. FISH allowed a better characterization of all samples analyzed. Nine cases (35%) showed reciprocal translocations, 15 (58%) unbalanced rearrangements, and two (7%) deletions. We describe two new recurrent aberrations. In 18 of the 26 cases analyzed the BP were located in band 1p36, which is 25.5 Mb long. In 14 of these 18 cases (78%) and without distinction between myeloid and lymphoid neoplasias, the BP clustered in a 2.5 Mb region located between 1p36.32 and the telomere. Interestingly, this region is contained in the 10.5 Mb cluster on 1p36.22-1pter defined in cases with 1p36 deletion syndrome. The 2.5 Mb region, located on 1p36.32-1pter, has a higher frequency of occurrence of tandem repeats and segmental duplications larger than 1 kb, when compared with the 25.5 Mb of the complete 1p36 band. This could explain its proneness for involvement in chromosomal rearrangements in hematological neoplasias
Assessment of minimal residual disease by next generation sequencing in peripheral blood as a complementary tool for personalized transplant monitoring in myeloid neoplasms
Patients with myeloid neoplasms who relapsed after allogenic hematopoietic stem cell
transplant (HSCT) have poor prognosis. Monitoring of chimerism and specific molecular markers
as a surrogate measure of relapse is not always helpful; therefore, improved systems to detect
early relapse are needed. We hypothesized that the use of next generation sequencing (NGS)
could be a suitable approach for personalized follow-up post-HSCT. To validate our hypothesis,
we analyzed by NGS, a retrospective set of peripheral blood (PB) DNA samples previously evaluated
by high-sensitive quantitative PCR analysis using insertion/deletion polymorphisms (indel-qPCR)
chimerism engraftment. Post-HCST allelic burdens assessed by NGS and chimerism status showed a
similar time-course pattern. At time of clinical relapse in 8/12 patients, we detected positive NGS-based
minimal residual disease (NGS-MRD). Importantly, in 6/8 patients, we were able to detect NGS-MRD
at time points collected prior to clinical relapse. We also confirmed the disappearance of post-HCST
allelic burden in non-relapsed patients, indicating true clinical specificity. This study highlights the
clinical utility of NGS-based post-HCST monitoring in myeloid neoplasia as a complementary specific
analysis to high-sensitive engraftment testing. Overall, NGS-MRD testing in PB is widely applicable
for the evaluation of patients following HSCT and highly valuable to personalized early treatment
intervention when mixed chimerism is detected
Assessment of minimal residual disease by next generation sequencing in peripheral blood as a complementary tool for personalized transplant monitoring in myeloid neoplasms
Patients with myeloid neoplasms who relapsed after allogenic hematopoietic stem cell
transplant (HSCT) have poor prognosis. Monitoring of chimerism and specific molecular markers
as a surrogate measure of relapse is not always helpful; therefore, improved systems to detect
early relapse are needed. We hypothesized that the use of next generation sequencing (NGS)
could be a suitable approach for personalized follow-up post-HSCT. To validate our hypothesis,
we analyzed by NGS, a retrospective set of peripheral blood (PB) DNA samples previously evaluated
by high-sensitive quantitative PCR analysis using insertion/deletion polymorphisms (indel-qPCR)
chimerism engraftment. Post-HCST allelic burdens assessed by NGS and chimerism status showed a
similar time-course pattern. At time of clinical relapse in 8/12 patients, we detected positive NGS-based
minimal residual disease (NGS-MRD). Importantly, in 6/8 patients, we were able to detect NGS-MRD
at time points collected prior to clinical relapse. We also confirmed the disappearance of post-HCST
allelic burden in non-relapsed patients, indicating true clinical specificity. This study highlights the
clinical utility of NGS-based post-HCST monitoring in myeloid neoplasia as a complementary specific
analysis to high-sensitive engraftment testing. Overall, NGS-MRD testing in PB is widely applicable
for the evaluation of patients following HSCT and highly valuable to personalized early treatment
intervention when mixed chimerism is detected